Download PDF
Horm Metab Res 1987; 19(11): 585-589
DOI: 10.1055/s-2007-1011887
Clinical

© Georg Thieme Verlag, Stuttgart · New York

Calcitonin Receptors of Human Osteoclastoma

G. C. Nicholson1 , M. A. Horton2 , P. M. Sexton1 , C. S. D'Santos1 , J. M. Moseley1 , B. E. Kemp1 , J. A. S. Pringle3 , T. J. Martin1
  • 1University of Melbourne, Department of Medicine, Repatriation General Hospital, Heidelberg, Victoria, Australia
  • 2I.C.R.F. Haemopoiesis Group, Department of Histopathology, St. Bartholomew's Hospital, West Smithfield, London, United Kingdom
  • 3Department of Morbic Anatomy, Royal National Orthopaedic Hospital, Stanmore, Middlesex, United Kingdom
Further Information

Publication History

Publication Date:
14 March 2008 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Osteoclast-rich cultures were prepared by disaggregation of osteoclastomas (giant cell tumour of bone) and settlement onto glass or plastic surfaces. Autoradiography using [125I]-salmon calcitonin ([125I]-sCT) revealed specific binding only to multinucleate giant cells (osteoclasts) and a minor population of mononuclear cells. [125I]-sCT competitive binding studies indicated a Kd of 5 × 10-10M and receptor number of approximately 1 million sites/osteoclast. sCT treatment resulted in a dose-dependent rise in cAMP (EC50 10-10M). Homogenates of an osteoclastoma also demonstrated specific binding of [125I]-sCT. Chemical cross-linking of a labelled synthetic sCT derivative, [125I]-[Arg11,18, Lys14]-sCT, using disuccinimidyl suberate, resulted in labelling of a receptor component of approximate Mr 85-90,000. The multinucleate giant cells (osteoclasts) of human osteoclastomas possess large number of CT receptors which exhibit the same binding kinetics and apparent Mr as those of other CT target cells.

Key-Words

Calcitonin - Receptor - Osteoclastoma - Osteoclast - Autoradiography - Cyclic AMP - Cross-linking

      >